Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023418 (leukemia)
 93,477 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Prochlorperazine (Compazine; PCPZ) is often used to limit cisplatin (CDDP)-induced emesis. However, recent studies in mice have shown that PCPZ protects against renal injury produced by treatment with various nephrotoxicants (e.g., MethylCCNU, mercuric chloride). Because renal toxicity remains a serious limitation to the effective use of CDDP, we conducted the present study to determine whether PCPZ could also protect against CDDP-induced renal injury. PCPZ treatment was shown to ameliorate CDDP-induced renal lesions in both rats and mice at doses and treatment schedules that were comparable with those used for alleviating chemotherapy-induced emesis. A PCPZ dose of 10 mg/kg x 2 offered complete protection against CDDP-induced increases in blood urea nitrogen (BUN) levels in mice, with significant protection occurring at a PCPZ dose as low as 5 mg/kg. Similarly, PCPZ ameliorated CDDP-induced increases in BUN, glucosouria, and enzymuria in F344 rats. PCPZ treatment did not affect the urinary excretion or renal tissue levels of total platinum or the plasma pharmacokinetics of free platinum. However, it did cause a marked reduction in the concentration of total plasma platinum (free platinum + protein-bound platinum). PCPZ was not found to affect the in vivo antitumor activity of CDDP against P388 leukemia. The present study suggests that PCPZ may be of therapeutic benefit when used with CDDP and provides a rational basis for the selection of antiemetic therapy.
 ...
PMID:Protection against cisplatin nephrotoxicity by prochlorperazine. 259 5

The current case study illustrates the innovative potential of combined medical and psychological treatment of postchemotherapy nausea and vomiting for cancer patients. A 58-yr-old male patient diagnosed with leukemia and on a weekly cytosine arabinoside (Ara-C) treatment protocol, experienced violent vomiting episodes approximately 3 hr. after each injection. Emesis was so severe that the patient considered terminating treatment. Control was attempted with antiemetics (Compazine, Reglan), an antianxiety agent (Valium), an hypnotic (Dalmane), canabinol, hypnosis, and relaxation training without success. A re-examination of these strategies employing experimental rigor and data-responsive experimental designs indicated how success can be achieved without the necessity of new interventions. The patient experienced complete emetic relief and at 3-yr. follow-up remained symptom-free.
 ...
PMID:Combined medical and psychological treatment of postchemotherapy nausea and vomiting: a case study. 278 Sep 30